Colivelin prolongs survival of an ALS model mouse

Biochemical and Biophysical Research Communications

Volumn 343, Issue 3, 2006, Pages 793-798

  Chiba, Tomohiro ^a   Yamada, Marina ^a   Sasabe, Jumpei ^a   Terashita, Kenzo ^a   Aiso, Sadakazu ^a   Matsuoka, Masaaki ^a   Nishimoto, Ikuo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ADNF; ALS; Colivelin; Humanin; Neuroprotection; SOD1

Indexed keywords

COLIVELIN; HUMANIN; HYBRID PROTEIN; NEUROTROPHIC FACTOR; PEPTIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HISTOLOGY; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; TREATMENT DURATION;

AGE OF ONSET; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; SPINAL CORD; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS;

MUS MUSCULUS;

EID: 33645944367     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.02.184     Document Type: Article

References (34)

1. Cleveland D.W., and Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2 (2001) 806-819 review
2. Bruijn L.I., Miller T.M., and Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27 (2004) 723-749 review
3. Turner M.R., Parton M.J., and Leigh P.N. Clinical trials in ALS: an overview. Semin. Neurol. 21 (2001) 167-175
4. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S.M., Berger R., Tanzi R.E., Halperin J.J., Herzfeldt B., Van den Bergh R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
5. Rabizadeh S., Gralla E.B., Borchelt D.R., Gwinn R., Valentine J.S., Sisodia S., Wong P., Lee M., Hahn H., and Bredesen D.E. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc. Natl. Acad. Sci. USA 92 (1995) 3024-3028
6. Ghadge G.D., Lee J.P., Bindokas V.P., Jordan J., Ma L., Miller R.J., and Roos R.P. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J. Neurosci. 17 (1997) 8756-8766
7. Niwa J., Ishigaki S., Hishikawa N., Yamamoto M., Doyu M., Murata S., Tanaka K., Taniguchi N., and Sobue G. Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. J. Biol. Chem. 277 (2002) 36793-36798
8. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., Chen W., Zhai P., Sufit R.L., and Siddique T. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
9. Brenneman D.E., and Gozes I. A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97 (1996) 2299-2307
10. Brenneman D.E., Hauser J., Neale E., Rubinraut S., Fridkin M., Davidson A., and Gozes I. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J. Pharmacol. Exp. Ther. 285 (1998) 619-627
11. Glazner G.W., Boland A., Dresse A.E., Brenneman D.E., Gozes I., and Mattson M.P. Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death. J. Neurochem. 73 (1999) 2341-2347
12. Chiba T., Hashimoto Y., Tajima H., Yamada M., Kato R., Niikura T.T., Terashita K., Schulman H., Aiso S., Kita Y., Matsuoka M., and Nishimoto I. Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo. J. Neurosci. Res. 78 (2004) 542-552
13. Chiba T., Yamada M., Hashimoto Y., Sato M., Sasabe J., Kita Y., Terashita K., Aiso S., Nishimoto I., and Matsuoka M. Development of a femtomolar-acting Humanin derivative named Colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of Colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J. Neurosci. 25 (2005) 10252-10261
14. Hashimoto Y., Niikura T., Tajima H., Yasukawa T., Sudo H., Ito Y., Kita Y., Kawasumi M., Kouyama K., Doyu M., Sobue G., Koide T., Tsuji S., Lang J., Kurokawa K., and Nishimoto I. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. Proc. Natl. Acad. Sci. USA 98 (2001) 6336-6341 (published erratum appears in Proc. Natl. Acad. Sci. USA 98 (2001) 12854)
15. Hashimoto Y., Niikura T., Ito Y., Sudo H., Hata M., Arakawa E., Abe Y., Kita Y., and Nishimoto I. Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults. J. Neurosci. 21 (2001) 9235-9245
16. Yamada M., Chiba T., Sasabe J., Nawa M., Tajima H., Niikura T., Terashita K., Aiso S., Kita Y., Matsuoka M., and Nishimoto I. Implanted cannula-mediated repetitive administration of Aβ25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav. Brain Res. 164 (2005) 139-146
17. Li M., Ona V.O., Guegan C., Chen M., Jackson-Lewis V., Andrews L.J., Olszewski A.J., Stieg P.E., Lee J.P., Przedborski S., and Friedlander R.M. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288 (2000) 335-339
18. Kawasumi M., Chiba T., Yamada M., Miyamae-Kaneko M., Matsuoka M., Nakahara J., Tomita T., Iwatsubo T., Kato S., Aiso S., Nishimoto I., and Kouyama K. Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice. Eur. J. Neurosci. 19 (2004) 2826-2838
19. Hashimoto Y., Suzuki H., Aiso S., Niikura T., Nishimoto I., and Matsuoka M. Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection. Life Sci. 77 (2005) 3092-3104
20. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H.S., Prats H., Vermeire S., Rutgeerts P., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34 (2003) 383-394
21. Storkebaum E., Lambrechts D., Dewerchin M., Moreno-Murciano M.P., Appelmans S., Oh H., Van Damme P., Rutten B., Man W.Y., DeMol M., Wyns S., Manka D., Vermeulen K., Van Den Bosch L., Mertens N., Schmitz C., Robberecht W., Conway E.M., Collen D., Moons L., et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 8 (2005) 85-92
22. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., and Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78
23. Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., and Hall E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39 (1996) 147-157
24. Pompl P.N., Ho L., Bianchi M., McManus T., Qin W., and Pasinetti G.M. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 17 (2003) 725-727
25. Nagano I., Ilieva H., Shiote M., Murakami T., Yokoyama M., Shoji M., and Abe K. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 235 (2005) 61-68
26. Chang-Hong R., Wada M., Koyama S., Kimura H., Arawaka S., Kawanami T., Kurita K., Kadoya T., Aoki M., Itoyama Y., and Kato T. Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 194 (2005) 203-211
27. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., and Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429 (2004) 413-417
28. Wang L.J., Lu Y.Y., Muramatsu S., Ikeguchi K., Fujimoto K., Okada T., Mizukami H., Matsushita T., Hanazono Y., Kume A., Nagatsu T., Ozawa K., and Nakano I. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. 22 (2002) 6920-6928
29. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., and Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
30. Manabe Y., Nagano I., Gazi M.S., Murakami T., Shiote M., Shoji M., Kitagawa H., and Abe K. Glial cell line-derived neurotrophic factor protein prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Neurol. Res. 25 (2003) 195-200
31. Schweizer U., Gunnersen J., Karch C., Wiese S., Holtmann B., Takeda K., Akira S., and Sendtner M. Conditional gene ablation of Stat3 reveals differential signaling requirements for survival of motoneurons during development and after nerve injury in the adult. J. Cell. Biol. 156 (2002) 287-297
32. Schabitz W.R., Kollmar R., Schwaninger M., Juettler E., Bardutzky J., Scholzke M.N., Sommer C., and Schwab S. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 34 (2003) 745-751
33. Suzuki S., Yamashita T., Tanaka K., Hattori H., Sawamoto K., Okano H., and Suzuki N. Activation of cytokine signaling through leukemia inhibitory factor receptor (LIFR)/gp130 attenuates ischemic brain injury in rats. J. Cereb. Blood Flow Metab. 25 (2005) 685-693
34. Pizzi M., Sarnico I., Boroni F., Benarese M., Dreano M., Garotta G., Valerio A., and Spano P. Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices. Mol. Cell Neurosci. 25 (2004) 301-311